paclitaxel has been researched along with lysophosphatidic acid in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Belinson, J; Escobar, P; Ganapathi, R; Michener, CM; Sengupta, S | 1 |
| Brindley, DN; Gaetano, C; Goping, IS; Samadi, N | 1 |
| Huang, Z; Ma, S; Wang, J; Zhang, G; Zhang, R | 1 |
| Bekele, RT; Brindley, DN; Goping, IS; Samadi, N; Schang, LM | 1 |
| Nagai, J; Uchida, H; Ueda, H | 1 |
| Daniel, LW; Davis, RR; Hollis, T; Rogers, LC; Said, N | 1 |
7 other study(ies) available for paclitaxel and lysophosphatidic acid
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Cell Adhesion; Cell Line, Tumor; Collagen Type I; Down-Regulation; Female; Humans; Laminin; Lysophospholipids; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Protein Isoforms; Up-Regulation | 2008 |
Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Ceramides; Humans; Lysophosphatidylcholines; Lysophospholipids; Melanoma; Membrane Potential, Mitochondrial; Multienzyme Complexes; Paclitaxel; Phosphodiesterase I; Phosphoric Diester Hydrolases; Pyrophosphatases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2009 |
Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; ets-Domain Protein Elk-1; Gene Expression; Humans; Lysophospholipids; Multienzyme Complexes; Osteopontin; Paclitaxel; Phosphodiesterase I; Phosphoric Diester Hydrolases; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-akt; Pyrophosphatases; Receptors, Lysophosphatidic Acid; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Up-Regulation | 2011 |
Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; G2 Phase; Humans; Lysophospholipids; Mitosis; Multienzyme Complexes; Paclitaxel; Phosphodiesterase I; Phosphoric Diester Hydrolases; Pyrophosphatases; Signal Transduction | 2011 |
Lysophosphatidic acid and its receptors LPA1 and LPA3 mediate paclitaxel-induced neuropathic pain in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Dizocilpine Maleate; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neuralgia; Paclitaxel; Pain Measurement; Phospholipases A2; Piperidines; Receptors, Lysophosphatidic Acid; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spinal Cord Dorsal Horn; Time Factors | 2014 |
Blocking LPA-dependent signaling increases ovarian cancer cell death in response to chemotherapy.
Topics: Antioxidants; Apoptosis; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; Female; Humans; Lysophospholipids; Ovarian Neoplasms; Paclitaxel; Reactive Oxygen Species | 2018 |